Apogee Therapeutics' (APGE) zumilokibart as a potential treatment in moderate-to-severe atopic dermatitis has met all primary and secondary endpoints "with high statistical significance" in a mid-stage trial, the clinical-stage company said Wednesday.
Mid-dose zumilokibart was well tolerated with a safety profile consistent with other treatments during the 16-week trial, the company said.
The company plans to begin late-stage trials in H2, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.